Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
Intellia Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Intellia Therapeutics's price to book ratio was 2.2× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.8× to 7.9×, with a median of 2.4×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.2× | +0.8 |
| 2025 | Dec 31, 2025 | 1.4× | +0.2 |
| 2024 | Dec 31, 2024 | 1.2× | −1.4 |
| 2023 | Dec 29, 2023 | 2.6× | −0.6 |
| 2022 | Dec 30, 2022 | 3.2× | −4.7 |
| 2021 | Dec 31, 2021 | 7.9× | −1.8 |
| 2020 | Dec 31, 2020 | 9.7× | +7.1 |
| 2019 | Dec 31, 2019 | 2.6× | +0.4 |
| 2018 | Dec 31, 2018 | 2.2× | −1.7 |
| 2017 | Dec 29, 2017 | 3.9× | +1.8 |
| 2016 | Dec 30, 2016 | 2.2× | – |
See a number that looks wrong?